Corvus Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CRVS Key Statistics
Stock Snapshot
As of today, Corvus Pharmaceuticals(CRVS) shares are valued at $21.00. The company's market cap stands at 1.74B, with a P/E ratio of -38.70.
On 2026-02-01, Corvus Pharmaceuticals(CRVS) stock traded between a low of $20.20 and a high of $21.71. Shares are currently priced at $21.00, which is +4.0% above the low and -3.3% below the high.
Corvus Pharmaceuticals(CRVS) shares are trading with a volume of 2.43M, against a daily average of 13.91M.
In the last year, Corvus Pharmaceuticals(CRVS) shares hit a 52-week high of $26.95 and a 52-week low of $2.54.
In the last year, Corvus Pharmaceuticals(CRVS) shares hit a 52-week high of $26.95 and a 52-week low of $2.54.
CRVS News
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $30 from $20 and keeps an Outperform rating on the shares. T...
Analyst ratings
100%
of 7 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.